Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mezigdomide, Carfilzomib, and Dexamethasone in Relapsed or Refractory Multiple Myeloma
NCT07348393Phase 2Not yet recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2026
- Primary completion
- Feb 2029
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of mezigdomide in multiple myeloma (MM), sponsored by Assistance publique - Hôpitaux de Paris. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
mezigdomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07348393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348393.